Doctronic Raises $40M to Expand AI-Powered Prescription Chatbot

The landscape of healthcare access is shifting, and a Utah-based startup called Doctronic is at the forefront of that change. The company, which aims to provide accessible healthcare through a chatbot-supported system, recently secured $40 million in Series B funding, bringing its total funding to $65 million in under a year. This infusion of capital signals a strong vote of confidence in Doctronic’s model, which combines initial symptom assessment via chatbot with telehealth consultations with human clinicians for a flat fee of $39.

Doctronic launched its first-in-the-nation experiment in prescription renewal using a chatbot earlier this year, and the company’s rapid growth is driving ambitious expansion plans. Founded in 2023, Doctronic began offering services with human clinicians in January 2025 and is now projecting revenue exceeding $10 million this year. The company intends to use the new funding to bolster its hiring efforts and scale its operations to meet increasing demand. Beyond direct patient care, Doctronic is also preparing to integrate its technology with a range of partners, including digital health companies, health systems, and payers.

A Hybrid Approach to Primary Care

Doctronic’s core service operates on a hybrid model. Patients initially interact with a chatbot to discuss their symptoms and health concerns. This initial assessment then informs a consultation with a human clinician via telehealth, where a diagnosis and treatment plan are determined. This approach aims to streamline the initial stages of care, potentially reducing wait times and improving access, particularly for those in underserved areas. The company positions itself as “the world’s most popular AI doctor,” though this claim hasn’t been independently verified and reflects the growing use of automated tools in healthcare.

The company’s rapid ascent raises questions about the evolving role of technology in healthcare delivery. The use of chatbots for initial symptom assessment is becoming increasingly common, with many healthcare providers now offering similar services. However, Doctronic’s model goes a step further by incorporating a human clinician into the process, aiming to balance the efficiency of automation with the expertise of a medical professional. This approach is similar to other telehealth platforms, but Doctronic’s emphasis on the chatbot as a front-conclude triage tool sets it apart. You can learn more about the growing telehealth market through STAT’s Health Tech newsletter.

Navigating Regulatory Scrutiny

Doctronic’s innovative approach hasn’t been without scrutiny. The company’s launch of prescription renewal via chatbot in Utah sparked debate about the appropriate level of regulation for AI-driven healthcare tools. The Food and Drug Administration (FDA) is currently grappling with how to oversee these technologies, balancing the potential benefits of increased access and efficiency with the demand to ensure patient safety. As reported by STAT News, the FDA is actively considering the regulatory framework for AI-powered healthcare solutions like Doctronic.

The core concern revolves around ensuring the accuracy and reliability of AI algorithms used in medical decision-making. While chatbots can effectively gather information and triage patients, they are not capable of independent medical judgment. The FDA’s role is to determine how to evaluate and approve these tools, ensuring they meet rigorous safety and efficacy standards. This is particularly important when it comes to prescription renewals, where errors could have serious consequences for patients. Mario Aguilar of STAT News has been closely following these developments, as highlighted in a recent LinkedIn post.

The Broader Implications for Healthcare

Doctronic’s success, and the regulatory discussions it has spurred, reflect a broader trend toward the integration of technology into healthcare. AI and machine learning are being used in a variety of applications, from drug discovery to medical imaging to personalized medicine. These technologies have the potential to revolutionize healthcare, but they also raise important ethical and practical considerations.

One key challenge is ensuring equitable access to these technologies. While telehealth and AI-powered tools can improve access for some patients, they may exacerbate existing disparities if they are not widely available or affordable. Another challenge is addressing concerns about data privacy and security. Healthcare data is highly sensitive, and it is crucial to protect it from unauthorized access and misuse. The potential for algorithmic bias is also a concern, as AI algorithms can perpetuate existing biases in healthcare if they are not carefully designed and validated.

Prescription Renewals and the Future of AI in Medicine

The specific focus on prescription renewals highlights a particularly sensitive area for AI application. Allowing AI to automatically renew prescriptions raises questions about the level of human oversight required to ensure patient safety. While routine prescription renewals may seem straightforward, they still require a careful review of a patient’s medical history and current condition. As STAT News reported, the debate centers on whether AI can reliably perform this task without the involvement of a human clinician.

The FDA’s decision on how to regulate AI-driven prescription renewals will likely have far-reaching implications for the future of AI in medicine. If the FDA adopts a permissive approach, it could pave the way for wider adoption of AI in other areas of healthcare. However, if the FDA adopts a more cautious approach, it could slow down the development and deployment of these technologies.

Doctronic’s trajectory, and the ongoing dialogue surrounding its model, underscores the need for a thoughtful and balanced approach to regulating AI in healthcare. The goal should be to harness the potential benefits of these technologies while mitigating the risks and ensuring patient safety. The company’s continued growth and expansion will undoubtedly be closely watched by regulators, healthcare providers, and patients alike.

Looking Ahead: The FDA is expected to release updated guidance on AI-driven medical devices in the coming months. This guidance will likely address issues such as data quality, algorithm transparency, and post-market surveillance. Doctronic, along with other companies developing AI-powered healthcare solutions, will need to adapt to these evolving regulatory requirements to ensure continued compliance and market access.